Start Submission Become a Reviewer

Reading: Plasma YKL-40 as a biomarker in patients with nonmetastatic bone and soft tissue sarcomas: a...

Download

A- A+
Alt. Display

Tumour Marker Prognostic Study

Plasma YKL-40 as a biomarker in patients with nonmetastatic bone and soft tissue sarcomas: a prospective exploratory clinical study

Authors:

Andrea P. Thorn ,

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, U-2161, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø DK-2100, DK
About Andrea P.

MD

X close

Mette L. Harving,

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK
About Mette L.

MD

X close

Gunnar S. Lausten,

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK
About Gunnar S.

MD

X close

Julia S. Johansen,

Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK
About Julia S.

MD, DMSc

X close

Michala S. Sørensen,

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK
About Michala S.

MD, PhD

X close

Michael M. Petersen

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK
About Michael M.

MD, DMSc

X close

Abstract

Purpose: YKL-40 is a glycoprotein with a role in inflammation, tissue remodeling, tumor angiogenesis, and protection against apoptosis. We hypothesized that high preoperative plasma YKL-40 in patients with nonmetastatic bone and soft tissue sarcoma (STS) is associated with short overall survival (OS), and that plasma YKL-40 is an independent predictor for OS.

Materials and methods: Plasma was collected preoperatively from 65 patients with nonmetastatic bone (n=14) or STS (n= 51) in the lower extremities (n= 43), the upper extremities (n=16) or the trunk wall/spine (n= 6). All patients underwent surgical cancer treatment. Twenty patients developed metastases during the follow-up period (minimum 5 y). The plasma concentration of YKL-40 was determined by enzyme-linked immunosorbent assay.

Results: Twenty-seven patients died [mean: 3.2 (range: 0.2.7.3) y postoperatively] and 38 patients were still alive after a follow-up of mean 6.9 (5.8.8.2) years postoperatively. Plasma YKL-40 was higher in patients who died during follow-up (P=0.008), in males (P =0.007) and in patients 61 years of age and above (P= 0.001). The 5-year OS was 68% and OS was lower in patients with high (≥ 95% percentile age-corrected) plasma YKL-40 (P= 0.021), age 61 years and above (P =0.013), high histologic malignancy grade (P =0.047) and male sex (P= 0.051). Multivariable analysis showed that only plasma YKL-40 (age-corrected (hazard ratio =2.80, 95% confidence interval: 1.13.6.91, P=0.026) and malignancy grade (hazard ratio = 9.9 × 107, 95% confidence interval: 0–∞, P =0.007) remained independent prognostic factors for OS.

Conclusions: High preoperative plasma YKL-40 was related to short OS in patients with nonmetastatic bone and STS and plasma YKL-40 (age-corrected) was an independent prognostic risk factor for OS.

How to Cite: Thorn AP, Harving ML, Lausten GS, Johansen JS, Sørensen MS, Petersen MM. Plasma YKL-40 as a biomarker in patients with nonmetastatic bone and soft tissue sarcomas: a prospective exploratory clinical study. International Journal of Surgery: Oncology. 2020;5(3):e87. DOI: http://doi.org/10.1097/IJ9.0000000000000087
13
Views
4
Downloads
Published on 06 May 2020.
Peer Reviewed

Downloads

  • PDF (EN)